Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM04ZUW)

Drug Name

Ponalrestat Drug Info

Synonyms

PONALRESTAT; statil; 72702-95-5; Ponalrestatum [Latin]; UNII-2CV0A5G64E; ICI-128436; ICI 128,436; CHEMBL7679; C17H12BrFN2O3; 2CV0A5G64E; 2-(3-(4-bromo-2-fluorobenzyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid; NCGC00024824-01; 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic acid; 1-Phthalazineaceticacid, 3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-; Ponalrestatum; 1-Phthalazineacetic acid, 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-; Prodiax; Ponalrestat [USAN:BAN:INN]; ISIS-5GLT2rx

Indication

Disease Entry	ICD 11	Status	REF
Gout	FA25	Discontinued in Phase 3	[1]
Diabetic complication	5A2Y	Investigative	[2]

Cross-matching ID

PubChem CID: 5278
ChEBI ID: CHEBI:93199
CAS Number: CAS 72702-95-5
TTD Drug ID: DM04ZUW

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sodium/glucose cotransporter 2 (SLC5A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[4]
RG7201	DMJRFYB	Type-2 diabetes	5A11	Phase 3	[5]
Remogliflozin etabonate	DMW4YK1	Type-1/2 diabetes	5A10-5A11	Phase 2	[6]
Remogli ozin-etabonate	DMZFV3E	Type-2 diabetes	5A11	Phase 2	[7]
------------------------------------------------------------------------------------

Drug(s) Targeting Aldose reductase (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[8]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[9]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[10]
Ranirestat	DMD5QRS	Diabetic neuropathy	8C0Z	Phase 3	[11]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[12]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[11]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[13]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[14]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[15]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Inhibitor	[3]
Sodium/glucose cotransporter 2 (SLC5A4)	TTN7Y4P	SC5A4_HUMAN	Blocker	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000017)
2	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
3	Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res. 1999 Sep-Oct;19(5B):4105-11.
4	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
5	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
6	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
8	Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
9	Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
10	Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
12	Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
13	ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
14	Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
15	A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.